Please try another search
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a near-patient testing system for triage and monitoring of disease progression. The Company's Symphony platform is a technology platform that provides measurements of key diagnostic biomarkers found in whole blood. The Symphony analyzer orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The Company's first product candidate, an IL-6 test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices (IVDs) market, including sepsis, cardio-metabolic diseases, cancer, and other diseases that require rapid tests.
Name | Age | Since | Title |
---|---|---|---|
Douglas Clark Wurth | 57 | 2017 | Independent Chairman |
Donald R. Chase | 74 | 2017 | Independent Director |
Svetlana Dey | 49 | 2015 | Director |
Frederick Schwartz Zeidman | 76 | 2021 | Independent Director |
Gary G. Gemignani | 57 | 2021 | Independent Director |
Indranil Dey | 60 | 2024 | Principal Financial, Accounting & Executive Officer, President, CEO and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review